Eyenovia

57 articles with Eyenovia

• Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12Company to host an investor conference call and webcast at 4:30pm ET on that day

  5/5/2021

  Eyenovia, Inc.  (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that the Company will release financial results for the first quarter ended March 31, 2021 on Wednesday, May 12, 2021, after market close.

• Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors

  4/1/2021

  Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia Haller, M.D., to its Board of Directors.

• Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results

  3/25/2021

  Announces MydCombi expected PDUFA date of October 28, 2021 Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; topline data on track for Q2 Company to host conference call and webcast today, March 25, at 4:30 pm ET NEW YORK, March 25, 2021

• Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis

  3/23/2021

  Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis

• Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25Company to host an investor conference call and webcast at 4:30pm ET on that day

  3/18/2021

  Eyenovia, Inc.  (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, March 25, 2021, after market close.

• Eyenovia to Participate in the 33rd Annual Roth Conference

  3/10/2021

  Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will participate in the 33rd Annual Roth Conference, which will be held on March 15-17, 2021.

• Eyenovia Announces FDA Acceptance of the MydCombi NDA

  3/2/2021

  Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for MydCombi™, a unique fixed combination mydriatic (pupil dilation) agent for potential use in the over 80 million comprehensive eye exams

• Eyenovia to Host Key Opinion Leader Webinar on PresbyopiaThe webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET

  2/16/2021

  Eyenovia, Inc ., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that it will host a Key Opinion Leader (KOL) webinar, entitled: “Presbyopia in Focus: Unlocking one of the Biggest Market Opportunities in Ophthalmology,” on Monday, February 22, 2021 at 1:00pm Eastern Time.

• Eyenovia to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase

  1/26/2021

  Presentation Focuses on the Challenges and Biases Facing Presbyopia Patients, and Potential Benefits of Treatment Delivered with Eyenovia’s Novel Optejet® Dispenser

• Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event

  1/6/2021

  Eyenovia, Inc ., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer, will participate in a panel discussion on presbyopia at the upcoming LifeSci Partners 10 th Annual Corporate Access Event. In December 2020, Eyenovia initiated the Phase 3 VISION-1 study (NTC04657172) o

• Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually

  12/29/2020

  Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has submitted a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) for MydCombi™, a unique fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic with a high precision s

• Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia

  12/16/2020

  Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the first set of patients has been enrolled in the Company’s Phase 3 VISION-1 study of MicroLine , its proprietary pilocarpine formulation delivered via its Optejet® dispenser, for the improvement in nea

• Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End

  12/3/2020

  Eyenovia, Inc ., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U. S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for MicroLine, a proprietary pilocarpine formulation for the improvement in near vision in patients with presbyopia. The Company intends to initiate t

• Eyenovia Reports Third Quarter 2020 Financial ResultsCompany to host conference call and webcast today, November 10, at 4:30pm ET

  11/10/2020

  Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today reported its financial results for the third quarter ended September 30, 2020. “During the third quarter and subsequent period, we continued to execute on our growth strategy to advance our late-stage ophthalmic portfolio while in parallel securing global development and commercialization pa

• Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10Company to host an investor conference call and webcast at 4:30pm ET on that day

  11/5/2020

  Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will release financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020, after market close.

• Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million

  10/13/2020

  Company reaffirms near term milestones for the Mydcombi™ (MicroStat) NDA and the MicroLine presbyopia program Phase III results

• Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12

  10/12/2020

  Bausch Health Companies Inc., Bausch + Lomb, and Eyenovia, Inc. announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12.

• Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting

  10/5/2020

  Optometry and ophthalmology doctors to present latest analyses and updates from studies of its MAP therapeutics for mydriasis, pediatric myopia and presbyopia

• Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference

  9/9/2020

  Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer and John Gandolfo, Eyenovia’s Chief Financial Officer, are scheduled to present at the 22 nd Annual H.C. Wainwright Global Investment Conference being held virtually on September 14-16, 2020. Deta

• Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering

  8/24/2020

  Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the underwriters of its previously announced public offering of common stock have fully exercised their option to purchase an additional 500,000 shares at the public offering price of $3.60 per share. After giving effect to the full exercise of the over-allotment option, the to